Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: Insulin secretory agents are commonly used to treat type 2 diabetes. However, traditional insulin secretory agents such as sulfonylureas and glinides have side effects of hypoglycemia. In recent years, researchers have discovered that berberine can inhibit the voltage-gated k+ channels of pancreatic β cell membrane and promote insulin secretion without causing hypoglycemia, because the glucose-lowering effects of berberine are only under hyperglycemic conditions or in a high-glucose-dependent manner. In order to shed light on the glucose-lowing effects of berberine in type 2 diabetes with different baseline fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1c), we conducted a meta-analysis of randomized controlled trials. Methods: We searched eight databases, which included PubMed, EMBASE, Web of Science, the Cochrane Library, and the Chinese databases such as Sino-Med, China National Knowledge Infrastructure (CNKI), Wanfang Database, and VIP Database for Chinese Technical Periodicals, for randomized controlled trials, with berberine as the intervention and patients with type 2 diabetes mellitus as subjects, published up until November 2021. We analyzed the glucose-lowing effects of berberine, including its effects on FPG, HbA1c and 2-h plasma blood glucose (2hPBG), by calculating weighted mean differences (WMD) and 95% confidence interval (CI). To assess the safety of berberine, we analyzed the incidence of total adverse events and hypoglycemia by calculating relative risk (RR) and 95% CI. Results: Thirty-seven studies involving 3,048 patients were included in the meta-analysis. The results showed that berberine could reduce FPG (WMD = -0.82 mmol/L, 95% CI (-0.95, -0.70)), HbA1c (WMD = -0.63%, 95% CI (-0.72, -0.53)), and 2hPBG (WMD = -1.16 mmol/L, 95% CI (-1.36, -0.96)), with all results being statistically significant. Subgroup analyses revealed that the glucose-lowering effect of berberine was associated with baseline mean FPG and HbA1c in type 2 diabetes. In addition, berberine alone or in combination with oral hypoglycemic agents (OHAs) in the treatment of T2DM did not significantly increase the incidence of total adverse events (RR = 0.73, 95% CI (0.55, 0.97), p = 0.03) and the risk of hypoglycemia (RR = 0.48, 95% CI (0.21, 1.08), p = 0.08). Conclusion: Berberine has a glucose-lowering effect, which is related to the baseline FPG and HbA1c levels of patients. Treatment with berberine may be safe since it does not increase the incidence of total adverse events and the risk of hypoglycemia. Systematic Review Registration:https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=292975, identifier CRD42021292975.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Microbiota in health and diseases
Hou, K., Wu, Z.-X., Chen, X.-Y., Wang, J.-Q., Zhang, D., Xiao, C., Zhu, D., Koya, J. B., Wei, L., Li, J., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00974-4 · Cited by 3,171
Self-citation6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403 · cited 1×
“It occurs in T2DM patients, when measurable glucose concentration is less than 3.9 mmol/L (Draznin et al., 2022).”
BackgroundInfluentialGarber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598 · cited 1×
“In addition, glinides also having side effects of hypoglycemia (Klein-Schwartz et al., 2016; Garber et al., 2020; Lv et al., 2020).”
BackgroundTreatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine
Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., Huo, L., Wang, M., Hong, J., Wu, P., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2404 · Cited by 573 · cited 8×
“Of these 37 studies, seven studies (Wang, 2008; Zhang et al., 2008; Gu et al., 2010; Xiang et al., 2011; Li, 2014; Lang and Zhu, 2016; Rashidi et al., 2018) compared BBR with placebo or no drug, while 20 studies (Liu, 2004; You and Liu, 2007; Liu and Hu, 2008; Xu, 2008; Sheng, 2009; Yang, 2010; Ye, 2010; Yin, 2011; Zh…”
BackgroundMethodResultInfluentialSelf-citationLan, J., Zhao, Y., Dong, F., Yan, Z., Zheng, W., Fan, J., & Sun, G. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.09.049 · Cited by 458 · cited 3×
“They have confirmed that BBR can improve blood glucose level, lipid metabolism, and inflammatory markers in diabetic patients, as well as treating hyperlipidemia and hypertension (Dong et al., 2012; Lan et al., 2015; Liang et al., 2019; Guo et al., 2021).”
BackgroundBerberine in the treatment of type 2 diabetes mellitus: A systemic review and meta-analysis
Dong, H., Wang, N., Zhao, L., & Lu, F. (2012) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2012/591654 · Cited by 225
Bray, J. J. H., Foster‐Davies, H., Salem, A., Hoole, A. L., Obaid, D. R., Halcox, J. P. J., & Stephens, J. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14399 · Cited by 194 · cited 1×
“There is growing evidence that chronic inflammation and some metabolic diseases are associated with insulin resistance, type 2 diabetes mellitus (T2DM) and systemic diabetic complications (Bray et al., 2021; Leite et al., 2021).”
BackgroundRashidi, H., Namjoyan, F., Mehraban, Z., Zakerkish, M., Ghaderian, S. B., & Latifi, S. M. (2018) · Jundishapur Journal of Natural Pharmaceutical Products · doi:10.5812/jjnpp.64180 · Cited by 28
Leite, M. M., Dutra, M. T., da Costa, M. V. G., Funghetto, S. S., Silva, A. D. O., de Lima, L. R., da Silva, I. C. R., Mota, M. R., & Stival, M. M. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111389 · Cited by 15
Research works printed but not linked: 66
- Budnitz, 2011, Emergency hospitalizations for adverse drug events in older Americans, N. Engl. J. Med., 365, 2002, 10.1056/NEJMsa1103053 · DOI · Paper page
- Cao, 2007, Clinical Research on Multiple factor intervention of improving the insulin resistance
- Chang, 2015, Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies, Biochem. Cell Biol., 93, 479, 10.1139/bcb-2014-0107 · DOI · Paper page
- Chang, 2020, Therapeutic effects of bcg vaccination on type 1 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials, J. Diabetes Res., 2020, 8954125, 10.1155/2020/8954125 · DOI
- Di Pierro, 2012, Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control, Diabetes Metab. Syndr. Obes., 5, 213, 10.2147/dmso.S33718 · DOI · Paper page
- Dong, 2017, Effect of berberine combined with metformin on serum inflammatory factors and islet function in type 2 diabetes mellitus, J. Clin. pathology, 37, 1418
- Fan, 2018, Effectiveness evaluation analysis on berberine tablets combination with metformin treating type 2 diabetes, Mod. Hosp., 18, 731, 10.3969/j.issn.1671-332X.2018.05.033 · doi:10.3969/j.issn.1671-332x.2018.05.033
- Finol-Urdaneta, 2012, Block of Kv1.7 potassium currents increases glucose-stimulated insulin secretion, EMBO Mol. Med., 4, 424, 10.1002/emmm.201200218 · DOI
- Gu, 2010, Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics, Talanta, 81, 766, 10.1016/j.talanta.2010.01.015 · DOI · Paper page
- Guo, 2018, Effect and mechanism of baicalein on insulin secretion in rats, Chin. Pharmacol. Bull., 34, 820, 10.3969/j.issn.1001-1978.2018.06.016 · doi:10.3969/j.issn.1001-1978.2018.06.016
- Guo, 2021, The effect of berberine on metabolic profiles in type 2 diabetic patients: A systematic review and meta-analysis of randomized controlled trials, Oxid. Med. Cell. Longev., 2021, 2074610, 10.1155/2021/2074610 · DOI · Paper page
- Jacobson, 2020, Ion channels of the islets in type 2 diabetes, J. Mol. Biol., 432, 1326, 10.1016/j.jmb.2019.08.014 · DOI
- Jiang, 2019, Effect of berberine hydrochloride tablets combined with metformin on blood glucose control and quality of life in patients with type 2 diabetes mellitus, Chronic Pathematology J., 8, 1228, 10.16440/j.cnki.1674-8166.20190912.004 · doi:10.16440/j.cnki.1674-8166.20190912.004
- Kakei, 2016, Glucose and GTP-binding protein-coupled receptor cooperatively regulate transient receptor potential-channels to stimulate insulin secretion [Review], Endocr. J., 63, 867, 10.1507/endocrj.EJ16-0262 · DOI
- Klein-Schwartz, 2016, Treatment of sulfonylurea and insulin overdose, Br. J. Clin. Pharmacol., 81, 496, 10.1111/bcp.12822 · DOI · Paper page
- Lang, 2016, Efficacy and safety of berberine in the treatment of type 2 diabetes mellitus, Health Guide, 35, 212
- Li, 2008, Advances in the study of berberine and its derivatives, Acta Pharm. Sin., 43, 773
- Li, 2021, Research progress of berberine in the treatment of diabetes and its complications, J. Hubei Univ. Sci. Technol. Sci., 35, 448, 10.16751/j.cnki.2095-4646.2021.05.0448 · doi:10.16751/j.cnki.2095-4646.2021.05.0448
- Li, 2008, Clinical observation of berberine combined with metformin in the treatment of type 2 diabetes mellitus, Hubei J. Traditional Chin. Med., 30, 34
- Li, 2014, Clinical efficacy and safety of berberine in the treatment of type 2 diabetes mellitus, 226
- Li, 2016, The clinical effect of sulfonylurea metformin and berberine in the treatment of diabetes, China Contin. Med. Educ., 8, 174
- Li, 2007, Effect of berberine combined with glipizide on type 2 diabetes, J. Clin. Res., 24
- Liang, 2019, Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: A systematic literature review and a meta-analysis, Endocr. J., 66, 51, 10.1507/endocrj.EJ18-0109 · DOI
- Liao, 2020, Action mechanism of berberine on diabetes mellitus and its complications, Med. Recapitulate, 26, 2637
- Ligtenberg, 1997, Effect of glibenclamide on insulin release at moderate and high blood glucose levels in normal man, Eur. J. Clin. Invest., 27, 685, 10.1046/j.1365-2362.1997.1710716.x · doi:10.1046/j.1365-2362.1997.1710716.x
- Liu, 2008, Effect of berberine on islet p-cell function in type 2 diabetes mellitus(damp-heat type), Chin. J. Inf. TCM, 15, 12
- Liu, 2004, Effect of berberine in adjuvant treatment of type II diabetes mellitus, J. Sichuan Traditional Chin. Med., 22, 46
- Liu, 2013, Effect of metformin combined with berberine in the treatment of incipient type 2 diabetes mellitus, zhejiang J. Integr. traditional Chin. West. Med., 23, 380
- Lv, 2020, Mechanisms and characteristics of sulfonylureas and glinides, Curr. Top. Med. Chem., 20, 37, 10.2174/1568026620666191224141617 · DOI
- Nagy, 2018, Glycogen phosphorylase inhibition improves beta cell function, Br. J. Pharmacol., 175, 301, 10.1111/bph.13819 · DOI
- Pratley, 2001, The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus, Diabetologia, 44, 929, 10.1007/s001250100580 · DOI · Paper page
- Riefflin, 2015, The effect of glibenclamide on insulin secretion at normal glucose concentrations, Diabetologia, 58, 43, 10.1007/s00125-014-3399-1 · DOI
- Rolland, 2002, G protein-independent activation of an inward Na(+) current by muscarinic receptors in mouse pancreatic beta-cells, J. Biol. Chem., 277, 38373, 10.1074/jbc.M203888200 · DOI · Paper page
- Sheng, 2009, The level of serum inflammatory factors in patients with T2DM and the impact of intervention after Berberine treatment
- Sun, Regulation of ion channels on insulin secretion in islet β cells, Life Sci. Res., 26, 59, 10.16605/j.cnki.1007-7847.2020.11.0262 · doi:10.16605/j.cnki.1007-7847.2020.11.0262
- Sun, 2017, Effect of Berberine on the serum levels of IL-10, IL-6 and CRP in patients with type 2 diabetes mellitus, J. Changchun Univ. Chin. Med., 33, 431
- Tokajuk, 2015, Antidiabetic drugs and risk of cancer, Pharmacol. Rep., 67, 1240, 10.1016/j.pharep.2015.05.005 · DOI
- Tong, 2019, Study on hypoglycemic and hypotensive effects and mechanisms of total glycosides of Plantaginis semen
- Wang, 2008, Effect of berberine on blood glucose, blood lipid and serum leptin of primary type 2 diabetes mellitus patients
- Wei, 2021, Effect of berberine combined with metformin and acarbose in the treatment of newly diagnosed type 2 diabetes mellitus, Contemp. Med. Symp., 19, 139, 10.3969/j.issn.2095-7629.2021.11.084 · doi:10.3969/j.issn.2095-7629.2021.11.084
- Wu, 2019, Compound traditional Chinese medicine in treatment of diabetes, J. Chin. Materia Medica, 44, 1104, 10.19540/j.cnki.cjcmm.20181212.001 · DOI
- Wu, 2020, Effect of berberine on atherosclerosis and gut microbiota modulation and their correlation in high-fat diet-fed ApoE-/- mice, Front. Pharmacol., 11, 223, 10.3389/fphar.2020.00223 · DOI · Paper page
- Xiang, 2011, A study of two anti-inflammatory drugs in patients with incipient type 2 diabetes, J. Pract. DIABETOLOGY, 7, 51
- Xing, 2017, Progress in pharmacological effects and clinical applications of berberine, Chin. J. Pharmacol. Toxicol., 31, 491, 10.3867/j.issn.1000-3002.2017.06.001 · doi:10.3867/j.issn.1000-3002.2017.06.001
- Xu, 2008, Effects of berberine and piogntazone oil type 2 diabetes acute insulin secretion and adiponecttn, Hainan Med., 19
- Xue, 2012, Efficacy of sulfonylureas combined with berberine metformin in the treatment of diabetes, Shaanxi J. Tradit. Chin. Med., 33, 1335
- Yang, 2008, Effect on different model intervention of improving the 2 diabetes insulin resistance
- Yang, 2010, Clinical observation of berberine hydrochloride combined with acarbose in the treatment of type 2 diabetes, Chin. J. Prim. Med. Pharm., 24, 3422
- Yang, 2014, Ionic mechanisms in pancreatic β cell signaling, Cell. Mol. Life Sci., 71, 4149, 10.1007/s00018-014-1680-6 · DOI
- Yang, 2020, Clinical study of berberine hydrochloride tablets combined with metformin in the treatment of incipient type 2 diabetes mellitus, Shanghai J. Traditional Chin. Med., 54
- Yao, 2015, Clinical observation of triple therapy in the treatment of type 2 diabetes mellitus, China Pharm., 29, 4107, 10.6039/j.issn.1001-0408.2015.29.26 · doi:10.6039/j.issn.1001-0408.2015.29.26
- Yao, 2013, Natural product vindoline stimulates insulin secretion and efficiently ameliorates glucose homeostasis in diabetic murine models, J. Ethnopharmacol., 150, 285, 10.1016/j.jep.2013.08.043 · DOI
- Ye, 2021, Analysis of the value of sulfonylureas and berberine metformin in the treatment of diabetes, Living Sci., 24, 263, 10.3969/j.issn.1672-9714.2021.18.263 · doi:10.3969/j.issn.1672-9714.2021.18.263
- Ye, 2010, Clinical efficacy of berberine treatment of diabetes, Mod. Hosp., 10, 9
- Yin, 2011, Effects of berberine hydrochloride on blood glucose, insulin and blood lipid in newly diagnosed type 2 diabetes mellitus, Acta Acad. Med. Xuzhou, 31, 40
- You, 2007, Clinical observation on the effect of berberine on urinary type IV collagen in diabetic patients, Chin. Hosp. Pharm. J., 6, 793
- Yu, 2020, Study on the effect of berberine hydrochloride combined with metformin on hypoglycemic effect and islet function in patients with T2DM
- Zhang, 2017, Analysis of the value of sulfonylureas and berberine metformin in the treatment of diabetes, DIABETES NEW WORLD, 20, 82
- Zhang, 2017, Efficacy of sulfonylureas combined with berberine metformin in the treatment of diabetes, Guidel. Health Care, 25, 252
- Zhang, 2012, Clinical observation of berberine in the treatment of type 2 diabetes, J. HEZE Med. Coll., 24, 27
- Zhang, 2016, Geniposide acutely stimulates insulin secretion in pancreatic β-cells by regulating GLP-1 receptor/cAMP signaling and ion channels, Mol. Cell. Endocrinol., 430, 89, 10.1016/j.mce.2016.04.020 · DOI
- Zhao, 2021, Berberine is an insulin secretagogue targeting the KCNH6 potassium channel, Nat. Commun., 12, 5616, 10.1038/s41467-021-25952-2 · DOI · Paper page
- Zhou, 2020, Research progress on chemical compositions of Coptidis Rhizoma and pharmacological effects of berberine, China J. Chin. Materia Medica, 45, 4561, 10.19540/j.cnki.cjcmm.20200527.202 · doi:10.19540/j.cnki.cjcmm.20200527.202
- Zhu, 2009, Effect of berberine combined with metformin in the treatment of type II diabetes mellitus, Chin. J. Misdiagn, 9, 788
- Zhu, 2015, Gliclazide combined with berberine in the treatment of type 2 diabetes mellitus, zhejiang J. Integr. traditional Chin. West. Med., 25, 915
- Zhu, 2020, Effect of berberine on hypoglycemic effect and gut microbiota in patients with newly diagnosed type 2 diabetes mellitus, J. TONGJI Univ. Sci., 41, 467
Cited by
Solnier, J., Zhang, Y., Kuo, Y., Du, M., Roh, K., Gahler, R., Wood, S., & Chang, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112567 · Cited by 47
Self-citationLiu, D., Zhao, H., Zhang, Y., Hu, J., & Xu, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1572197 · Cited by 24
“Furthermore, a 2023 meta-analysis (Xie et al., 2022) reported that berberine intervention signi fi cantly reduced FPG and 2hOGTT levels; however, this meta-analysis only included T2DM patients, while our meta-analysis evaluated berberine ’ s effect in a broader population.”
Self-citationWang, J., Bi, C., Xi, H., & Wei, F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1455534 · Cited by 13
Dumitru, C. N., Marcu, T., Dumitru, A. O., Tudor, S. S., Ferțu, I. D., Elisei, A.-M., & Goroftei, L. (2026) · Pharmaceuticals · doi:10.3390/ph19081313 · Cited by 2
“Meta-analyses of randomized trials confirm significant reductions in glycated hemoglobin, fasting glucose and lipid profile with berberine [25–28], and its metabolic efficacy has been compared, in some syntheses and combination clinical studies, with that of common oral hypoglycemic agents [29–31].”
Metadata
- Authors
- Xie, W., Su, F., Wang, G., Peng, Z., Xu, Y., Zhang, Y., Xu, N., Hou, K., Hu, Z., Chen, Y., & Chen, R.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2022-11-16
- Volume
- 13
- Pages
- 1015045-1015045
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W4309317312
- Cited by
- 91
- References
- 10
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis. https://app.cochat.ai/papers/10.3389/fphar.2022.1015045
- The paper
- Xie, W., Su, F., Wang, G., Peng, Z., Xu, Y., Zhang, Y., Xu, N., Hou, K., Hu, Z., Chen, Y., & Chen, R. (2022). Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2022.1015045
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.